BBHC
KERX

Brown Brothers Harriman & Co’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-63
Closed – – 1257
2017
Q4 		$0 Buy
+63
New +$347 ﹤0.01% 1232

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Brown Brothers Harriman & Co's KERX Position: Q1 2018 in Review

Brown Brothers Harriman & Co sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2018, closing a stake of 63 shares.

Brown Brothers Harriman & Co first reported a position in KERX in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 125 funds tracked by Wall St. Rank hold KERX as of Q1 2018.

  • Brown Brothers Harriman & Co reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 63 Keryx Biopharmaceuticals Inc shares in Q1 2018.
  • Brown Brothers Harriman & Co first reported a position in Keryx Biopharmaceuticals Inc in Q4 2017 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Keryx Biopharmaceuticals Inc position peaked at $0 in Q4 2017.
  • 125 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2018.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2018, filed 14 May 2018.